Warning letter
Atlas Pharmaceuticals, LLC: warning letter of Sep 10, 2018
FDA warning letter 564139 · San Francisco District Office
Key facts
| Reference number | 564139 |
|---|---|
| Company | Atlas Pharmaceuticals, LLC |
| Subject | Compounding Pharmacy/Adulterated Drug Products |
| Issue date | Sep 10, 2018 |
| Posted date | Sep 25, 2018 |
| Issuing office | San Francisco District Office |
| Product type | Drugs |
| CFR sections cited | 211.188, 201.115, 211.192, 200.10(b), 211.42(c)(10)(iv), 211.42(c)(10)(v), 211.67(a), 211.113(b), 211.160(b), 210.1(b) |
| Inspection city | Phoenix |
| Inspection ZIP | 85085 |
| Inspection start date | Aug 15, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: